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Abstract 
Aims Regression of albuminuria and renal fibrosis occurs in patients with diabetic 
nephropathy (DN) following tight control of blood glucose and blood pressure, however the 
pathways that promote regression remain poorly understood and we wished to characterise 
these using a rodent model.  
Methods Diabetes was induced with streptozotocin in Cyp1a1mRen2 rats and hypertension 
was generated by inducing renin transgene expression with dietary indole-3-carbinol (I-3-C) 
for 28wks. At this point an ‘injury cohort’ was culled, while in a ‘reversal cohort’ glycaemia 
was tightly controlled using insulin implants and blood pressure normalised by withdrawing 
dietary I-3-C for a further 8wks. Pathways activated during and following reversal of diabetes 
and hypertension were assessed by microarray profiling. 
Results Tight control of blood glucose and blood pressure reduced albuminuria and renal 
hypertrophy, but had no impact on renal fibrosis. 85 genes were up-regulated specifically 
during the injury phase, including genes encoding multiple myofibroblast and extracellular 
matrix (ECM) proteins. Conversely, 314 genes remained persistently elevated during reversal 
including genes linked to innate/adaptive immunity, phagocytosis, lysosomal processing and 
degradative metalloproteinases (MMPs). Despite increased MMP gene expression, MMP 
activity was suppressed during both injury and reversal, in association with up-regulation of 
tissue inhibitor of metalloproteinase-1 (TIMP-1) protein. Physical separation of the TIMP-
1/MMP complexes during zymography of tissue homogenate restored MMP activity.  
Conclusion Normalisation of blood glucose and pressure ameliorates albuminuria and 
inhibits excess ECM production, however persistent TIMP-1 expression hinders attempts at 
ECM remodelling. Therapies which counteract the action of TIMPs may accelerate scar 
resolution.  
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Introduction 
As with many chronic diseases, the rate of progression of diabetic nephropathy (DN) depends 
on the net balance between the severity of the injury and the body’s reparative capacity, such 
that a reduction in injurious stimuli may facilitate regression of disease. There is precedent 
for this in diabetic kidney disease as tight control of the pre-eminent factors promoting injury, 
namely hyperglycaemia and hypertension, can result in regression of microalbuminuria
1
. 
Furthermore, a reduction in glomerulosclerosis
2
 and tubulointerstitial fibrosis
3
 has been 
documented in patients with moderately advanced DN who achieved sustained 
normoglycaemia following pancreas transplantation. Resolution of fibrosis is, however, a 
protracted process, requiring up to 10 years of normoglycaemia.   
While considerable research has focused on the pathways that promote disease, less is known 
about mechanisms of repair. This is partly due to the scarcity of kidney tissue available from 
patients during regression of DN, as there is little rationale for performing renal biopsy in this 
setting. Furthermore, the regression has been difficult to study in an experimental setting as 
traditional animal models exhibit only the earliest features of human disease
4
. 
We recently described a rodent model in which hyperglycaemic and renin-dependent 
hypertension synergise to promote transcriptomic and pathological changes typical of 
moderately advanced human DN
5
. An attractive feature of this model is that the 
Cyp1a1mRen2 rats have a copy of the murine ren2 cDNA integrated into their genome under 
the control of the Cyp1a1 promoter, such that the severity of hypertension can be regulated 
by altering the dietary concentration of indole-3-carbinol (I-3-C)
6
.  
The aim of the current study was to identify pathways that were differentially regulated in the 
kidney during and following reversal of hyperglycaemia and hypertension in the 
Cyp1a1mRen2 model using systematic gene expression profiling. 
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Materials and methods 
Animal studies 
Diabetes was induced in adult, male Cyp1a1mRen2 Fisher rats with an intravenous bolus of 
20mg/kg streptozotocin and confirmed by blood glucose >15mM three days later. Thereafter, 
blood glucose was maintained between 20-30mM with serial subcutaneous insulin implants 
(Research Pack, Linshin, Canada). Two weeks after streptozotocin, 0.125% I-3-C (Sigma, 
UK) was added to the diet to maintain tail-cuff systolic BP at approximately 200mmHg. At 
the end of the 28wk ‘injury phase’ the animals were randomised into two groups matched for 
blood glucose, blood pressure and albuminuria. An injury cohort (n=10) was culled 
immediately, while in a reversal cohort (n=9) the blood glucose concentration was tightly 
controlled by increasing the frequency/dose of the insulin implants and I-3-C was removed 
from the diet to facilitate normalisation of blood pressure for a further eight weeks (Fig 1A). 
Six age-matched, male, non-diabetic, non-hypertensive controls were culled at 28wks. 
Procedures were performed under UK Home Office licence following approval by the Ethics 
Committee, University of Edinburgh. 
Quantification of proteinuria and renal function 
24hr urine collections were obtained at baseline, 9, 18 and 28wks and at 1, 2, 4, 6 and 8wks 
after reversal. Tail vein blood samples were taken at baseline, after 28 weeks of injury and 
eight weeks of reversal. Albumin and creatinine measurements were performed on a Cobas 
Fara centrifugal analyser (Roche Diagnostics Ltd, UK) using a commercial 
immunoturbidimetric assay (Microalbumin Kit, Olympus Diagnostics Ltd, Watford, UK) and 
a creatininase-based enzymatic method (Alpha Laboratories Ltd, Eastleigh, UK), 
respectively.  
Immunohistochemistry 
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Immunohistochemistry was performed using standard protocols on 4M methacarn-fixed 
sections (for transgelin, ED-1, CD3, WT1) or paraformaldehyde-fixed, paraffin-embedded 
sections following antigen retrieval with 10mM Tris Base/1mM EDTA (for inducible nitric 
oxide synthase (iNOS) and mannose receptor). Primary antibodies included: rabbit anti-
mouse transgelin (1:8,000, Abcam, Cambridge, UK), mouse anti-rat ED-1 (1:100, AbD 
Serotec, Kidlington, UK), rabbit anti-rat iNOS (1:2,500, Abcam, Cambridge, UK), rabbit 
anti-rat Mannose Receptor (1:1,500, Abcam, Cambridge, UK), rabbit anti-human CD3 
(1:100, DAKO, Cambridge, UK) and rabbit anti-human WT1 (1:200, Santa Cruz 
Biotechnology, Santa Cruz, CA, USA) followed by a species-appropriate, biotinylated 
secondary antibody (1:300, Vector Labs, Peterborough, UK) and detection with the Vector 
ABC kit and DAB. Sections were also stained for periodic acid-schiff and picrosirius red 
with glomerulosclerosis and tubulointerstitial fibrosis indices determined from a mean of 150 
glomeruli and 25 x200-power tubulointerstitial fields per animal, respectively. For both 
indices a semi-quantitative scoring system was devised: grade 0: normal; grade 1: <25%; 
grade 2: 25-50%; grade 3: 50-75% and grade 4: >75% of area sclerosed/fibrosed. 
Glomerulosclerosis/TIF indices = (1 x n1) + (2 x n2) + (3 x n3) + (4 x n4)/total number of 
glomeruli/tubulointerstitial fields scored, where n1-n4 are the number of fields in each of 
grades 1-4. The mean number of infiltrating ED-1
+
, iNOS
+
 and MR
+
 macrophages and CD3
+
 
T-cells were obtained from 20-30 x400 tubulointerstitial fields/animal. The mean number of 
glomeruli was calculated after counting the total number of glomeruli per kidney section in 
each animal. The mean glomerular surface area was obtained by manually tracing the 
glomerular tuft of all hilar glomeruli present in a kidney section from each animal (20-30 
glomeruli per section) using an image analysis system (Adobe Photoshop Software). The 
mean number of WT1+ cells was calculated by counting the number of WT1
+
 nuclei in 20-30 
hilar glomerular cross-sections/animal. 
Gene expression analysis 
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RNA was extracted (Nucleospin RNAII kit, Macherey-Nagel, Duren, Germany) from snap-
frozen, homogenised renal cortices from representative animals from the injury cohort (n=8), 
the reversal cohort (n=4) and from controls (n=4) and hybridized to the Affymetrix Rat 
Genome 230 2.0 GeneChip. Data were extracted by GCOS software, and CEL ﬁles were 
further processed in Bioconductor, normalized by RMA in the Affy module, and analysed 
with the Limma package. Data are available in the ArrayExpress database (accession no:E-
MEXP-3739).  Pathway enrichment analysis was performed using the Gene Ontology/KEGG 
tools on DAVID, Metacore (GeneGo, St. Joseph, MI, USA) or Ingenuity (Qiagen, Redwood 
City, CA, USA). The relative expression of selected genes was validated in all animals by 
rtPCR using the 2-Ct method and Taqman assays (Applied Biosystems, Cheshire, UK): 
tagln:Rn01642285_g1; acta2:Rn01759928_g1; col1a1:Rn01463848_m1; 
fn:Rn00569575_m1; foxp3:Rn01525092_m1; mmp2:Rn01538170_m1; 
mmp7:Rn00689241_m1; mmp12:Rn00588640_m1; mmp14:RN00579172_m1; 
timp1:Rn01430873_g1; timp2:Rn00573232_m1; timp3:Rn00441826_m1. 
Metalloproteinase activity assay/zymography 
For the MMP activity assay/zymography, frozen renal cortex was homogenised (20%v/w) in 
RIPA lysis buffer or 150mM NaCl/1% Triton X-100/50mM Tris, respectively, and 
normalised for protein concentration (BCA assay, Thermo Scientific, Northumberland, UK). 
Metalloproteinase activity was assessed using the EnzChek Gelatinase/Collagenase Assay 
Kit (Invitrogen) employing the gelatinase/collagenase inhibitor 1,10-phenanthroline, 
monohydrate as a negative control. 
For substrate zymography polyacrylamide gels were co-polymerized with either gelatin 
(1mg/ml) or collagen (0.2mg/ml) and 100µg lysate per lane was separated by electrophoresis. 
Gels were washed twice with 2.5% Triton X-100, incubated at 37°C for 48-72 hours (Bio-
Rad, Hercules, CA), stained with 0.05% Coomassie Brilliant Blue (VWR, Radnor, USA) in A
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methanol/acetic acid/water and de-stained in aqueous 4% methanol/8% acetic acid. Band 
intensities were quantified on Software Odyssey v.3.0 (Li-Cor, Lincoln, USA). 
 
Western blotting 
Renal cortices were homogenised in 150 mM NaCl/20 mM Tris-HCl/1mM EDTA (pH8)/1% 
Triton-X 100/protease inhibitor cocktail (Roche, Switzerland). 30 μg protein was separated 
on a 10% SDS gel, transferred to a membrane and incubated with rabbit anti-rat TIMP-1 
antibody (1: 1000, Biorbyt, Cambridge, UK) or rabbit anti-rat β-actin (1 : 1000, Abcam, 
Cambridge, UK) and horseradish peroxidase-conjugated anti-rabbit IgG secondary (1 : 2,000, 
Dako, Hamburg, Germany). Recombinant TIMP1 (RayBiotech, Norcross, USA) constituted a 
positive control. Blots were developed using a chemiluminescence kit (ECL Plus, Amersham, 
GE Healthcare, Buckinghamshire, UK), imaged on a Versadoc system (Bio-Rad, Hercules, 
USA) and densitometry was performed using Adobe Photoshop Software. 
Statistical analysis 
Data are means (±SEM) and medians (IQR) where normal or skewed, respectively. Groups 
were compared by 1-way ANOVA followed by Bonferroni corrections (following log-
transformation of non-parametric data). The Benjamini-Hochberg false-discovery rate 
method was used to correct for multiple testing in microarray analysis. 
 
Results 
Biochemical parameters 
During the 28wk injury phase, there was a progressive rise in albuminuria (Fig 1B-D). In the 
reversal cohort, an increase in the dose and frequency of subcutaneous insulin implants 
ameliorated hyperglycaemia (Fig 1B) while removal of 1-3-C from the diet normalised 
systolic blood pressure (Fig 1C). This led to a rapid initial reduction in albuminuria probably 
related to haemodynamic factors followed by a more gradual decline, though it remained 
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persistently greater than in controls (Fig 1D). After 28wks of diabetes and hypertension, 
creatinine clearance was not significantly different in either the injury (2.45±0.87ml/min) or 
reversal cohorts (2.46±0.30ml/min) compared with controls (2.37±0.63ml/min, p=0.48 and 
p=0.64, respectively) and remained unchanged following 8wks of relative normalisation of 
glycaemia and blood pressure (2.59±0.63ml/min, p=0.56 v peak injury).  
Pathological parameters 
The mean percentage kidney:body weight ratio increased in the injury cohort compared with 
controls (0.47±0.06 v 0.30±0.01, p<0.001, Table 1). This reduced in the reversal cohort 
(0.36±0.03, p<0.001 v injury cohort) though it remained significantly (p<0.05) greater than in 
controls. There was a marked increase in the glomerulosclerosis and tubulointerstitial fibrosis 
indices in the injury cohort compared with controls (Fig 2). After 8wks of tight blood glucose 
and blood pressure control, the reversal cohort exhibited similar severity of 
glomerulosclerosis and tubulointerstitial fibrosis to the injury cohort, and significantly greater 
levels than controls (Fig 2). There were no differences between the groups in the mean hilar 
glomerular cross-sectional area or mean number of glomeruli per tissue section (Table 1). 
While there was a trend towards a reduction in the mean number of WT1
+
 podocytes/hilar 
glomerular cross-sectional in the injury and reversal cohorts compared with control animals, 
this did not reach statistical significance (p=0.07, Suppl Figure). 
Microarray data  
To identify pathways activated in the kidney during and following reversal of 
hyperglycaemia and hypertension, we compared gene expression patterns in the renal cortices 
of the injury and reversal cohorts with controls. 677 genes were up-regulated >1.5-fold 
(corrected p<0.01) in the injury cohort compared with controls. The expression of 85 of these 
fell >50% towards control levels following 8wks of reversal of hyperglycaemia and 
hypertension (‘Up-regulated specifically during injury’, Fig 3, Suppl Table 1). Conversely the 
expression of 314 genes remained persistently increased (increased further or fell <20% 
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compared to peak injury) despite 8wks of relative normoglycaemia and normotension 
(‘Persistently up-regulated’, Fig 3, Suppl Table 2).   
145 genes were down-regulated >50% in the injury cohort compared with controls (corrected 
p<0.01). The expression of 80 of these 145 genes did not increase significantly (<20% 
increase compared to peak injury) after 8wks of reversal of hyperglycaemia and hypertension 
and were designated as ‘persistently repressed’ (Figure 3 and Suppl Table 3). Conversely, 
there was a significant (corrected p<0.05) increase in the expression of 4 of the 145 down-
regulated genes (Von Willebrand factor, phospholipase A2 group 6, malic enzyme 1, and 
lactate dehydrogenase D), such that they were no longer differentially expressed compared to 
controls (designated ‘de-repressed’ Fig 3).  
Finally, the expression of a small number of genes did not change during injury but was 
significantly (corrected p<0.05) down-regulated (n=19) or up-regulated (n=5) after 8wks of 
reversal of hyperglycaemia or hypertension (Fig 3, Suppl Table 4). Remarkably, 12/19 genes 
(63%) that were down-regulated specifically during reversal encoded for proteins selectively 
expressed on endothelial cells. 
Validation of microarray findings 
Pathway analysis using both Ingenuity and Metacore (Table 2) determined that many of the 
genes that were up-regulated specifically during injury are implicated in acute phase 
response, complement/coagulation pathways and regulation of the ECM. The pattern of 
expression of selected ECM-related genes was validated by real-time PCR (Fig 4A). 
Amongst the genes whose expression remained persistently up-regulated during reversal 
there was an over-representation of genes implicated in innate and adaptive immunity, ECM 
degradation, Wnt pathway and apoptosis (Table 3). Consistent with the transcriptomic data, 
increased numbers of macrophages were found in both the injury and reversal cohorts (Fig 
4Bi), however there was a switch in macrophage phenotype, with increased classically 
activated iNOS
+
 macrophage infiltration occurring exclusively during injury (Fig 4Bii), 
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whereas infiltrates of mannose receptor (MR)
+
 macrophages were observed both during and 
following reversal of injury (Fig 4Biii). T-cells infiltrated the interstitium of both the injury 
and repair cohorts (Fig 4Ci) and interestingly, there was persistent increase in expression of 
the foxp3 gene, a marker of regulatory T-cells (TReg) (Fig 4Cii).  
Metalloproteinase activity assays 
Real-time PCR confirmed that the expression of multiple matrix metalloproteinase (MMP) 
genes was increased during injury, with mmp-7 and -12 remaining up-regulated or even 
increasing during reversal, while mmp-2, and -14 partially reverted towards control levels 
(Fig 5A). Despite the increase in MMP gene expression, there was a paradoxical decrease in 
MMP activity in the renal cortex during both injury and reversal as assessed by gelatinase 
and collagenase activity assays (Fig 5B). Gene expression of tissue inhibitor of 
metalloproteinase-1 (timp-1), and to a lesser extent timp-2, increased during injury (Fig 5Ci), 
and while expression of the timp-1 gene fell significantly during reversal, TIMP-1 protein 
remained persistently elevated compared to controls (Fig 5Cii). In contrast to the reduced 
MMP activity in whole kidney lysates, when TIMPs were physically separated from the 
MMPs during gel zymography, MMP-2 (72kD band in gelatinase zymogram, Fig 5Di) and 
MMP-1 (52kD band in collagenase zymogram, Fig 5Dii) activity in both the injury and 
reversal cohorts tended to be greater than in controls, and indeed MMP-1 activity was 
significantly greater during reversal than in controls. 
 
Discussion 
In our rodent model of moderately advanced DN, relative normalisation of hyperglycaemia 
and hypertension for eight weeks reduced albuminuria and renal hypertrophy but did not lead 
to regression of established renal scarring. This is in contrast to previous studies in which scar 
regression was observed after a similar duration of tight glycaemic control or renin-
angiotensin system blockade, however these studies were performed in non-diabetic models
7
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9
 or in models of early diabetic injury
10
. The current findings must be considered in the 
context of human disease, where regression of fibrosis in the diabetic kidney is a protracted 
process, requiring ten years of normoglycaemia following pancreatic transplantation, with no 
improvement documented after five years
2
.  
There is scant data regarding how the diabetic kidney responds to a period of tight blood 
glucose and blood pressure control. The patterns of gene expression in the kidney of diabetic 
and hypertensive Cyp1a1mRen2 rats have been shown to closely reflect those in human 
disease
5
, therefore we considered it an appropriate model in which to dissect the pathways 
activated in the kidney during and following reversal of hyperglycaemia and hypertension. 
Our study provides insight into the mechanisms that promote fibrosis and a rationale as to 
why the diabetic kidney is so resistant to repair. 
The 85 genes that were up-regulated specifically during the injury phase were markedly 
enriched for genes encoding ECM proteins, suggesting that tight blood glucose and blood 
pressure control was sufficient to switch off excess ECM production and prevent progression 
of fibrosis. Within this group were multiple myofibroblast markers including transgelin, 
platelet-derived growth factor-β and -smooth muscle actin, which is consistent with the role 
of the myofibroblast as the chief scar-producing cell in the kidney
11
. We hypothesise that 
many of the other genes that are similarly up-regulated specifically during the injury phase 
(Suppl table 1) may also be implicated in the pro-fibrotic response, and evidence from 
fibrosis in other organs supports this concept. The lysyl oxidase and lysyl oxidase-like 2 
genes are both up-regulated in liver and lung fibrosis, where they mediate collagen cross-
linkage, rendering it resistant to degradation.
12
 Similarly, the cadherin 11 gene is up-regulated 
in idiopathic pulmonary fibrosis with administration of a neutralising antibody against 
CDH11 proving beneficial in experimental lung fibrosis
13
. In addition, pathway analysis of 
genes up-regulated during the injury phase demonstrated enrichment with acute phase A
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response and complement genes, which are classically associated with acute renal injury, but 
have been recently recognised to be activated in human DN
14
. 
We observed a much larger group of genes that remain up-regulated despite tight blood 
glucose and blood pressure control. We hypothesise that these may constitute a thwarted 
attempt at repair, remaining persistently up-regulated in a bid to restore normal tissue 
homeostasis. Prominent amongst these persistently up-regulated genes are those linked to 
innate and adaptive immunity. T-cell infiltration has been documented in the kidneys of 
patients with DN
15
, however their role is uncertain as they may promote albuminuria
16
, 
whereas specific subsets, such as Treg cells, may mediate repair
17
. The persistent increase in 
gene expression of the Treg cell marker, foxp3, supports such a reparative role following 
reversal of diabetes and hypertension. Macrophages also may have both detrimental and 
beneficial effects, with classically activated macrophages promoting nephropathy
18
, while 
‘reparative’ macrophages are essential both for regeneration of injured renal tubules and for 
resolution of fibrosis
19
. Our data suggests that during hyperglycaemia and hypertension, there 
is an influx of injurious classically activated iNOS
+
 macrophages, which become deactivated, 
emigrate or apoptose during the reversal phase. Conversely, MR
+
 ‘reparative’ macrophages 
infiltrate the diabetic kidney and persist despite tight blood glucose and blood pressure 
control. In parallel, there is persistent up-regulation of genes that encode macrophage proteins 
involved in matrix degradation, phagocytosis and lysosomal processing, a genetic signature 
that is characteristic of a reparative macrophage phenotype
20
.  Furthermore, the Wnt and 
Ephrin, and Nrf2 signalling pathways were over-represented amongst genes that remained 
up-regulated despite reversal of diabetes and hypertension, which is of interest, given that all 
these pathways have been associated with repair in other models of renal injury
21-23
. Taken 
together, the switch in macrophage polarisation and pathway analysis suggests attempts at 
repair are initiated, however we cannot exclude the possibility that some of the gene A
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expression changes are due to residual injury due to modest hyperglycaemia or ongoing 
albuminuria. 
Our study offers insight as to why the reparative pathways that are initiated in the diabetic 
kidney are relatively ineffectual in degrading excess ECM. Despite a marked increase in 
MMP gene expression, the MMP activity was reduced to a comparable level to that observed 
following addition of a biochemical inhibitor of MMP activity. This suggests that an 
endogenous inhibitor of MMPs may be present, and a likely candidate is TIMP-1 protein, 
which is persistently expressed in both injury and reversal phases. Furthermore, the non-
covalent nature of the TIMP:MMP interaction facilitated physical separation of the TIMPs 
from MMPs during gel zymography, and under these conditions the activity of both a 
collagenase, MMP-1, and a gelatinase, MMP-2, increased substantially. TIMP-1 is also up-
regulated in human diabetic nephropathy
24
 and strategies to block the action of TIMP-1 in 
vivo, thereby facilitating the ECM-degrading activity of the up-regulated MMPs, may be an 
attractive therapeutic target in DN. While this strategy has proven beneficial in rodent models 
of cirrhosis
25
, the role of MMPs and TIMPs in renal fibrosis is complex as MMPs may also 
exert detrimental effects by activating multiple pro-inflammatory pathways, therefore the 
efficacy and safety of TIMP-1 antagonism must be confirmed initially in rodent studies. 
In our microarray profiling we identified that the majority of the 145 genes which were 
down-regulated in the injury cohort continued to be expressed at reduced levels during 
reversal. While this may reflect an important functional transcriptomic response of surviving 
nephrons to injury, it is perhaps more likely that it simply reflects a loss of nephron mass as 
this subset included structural genes, such as nephrin. Consistent with this hypothesis, there 
was a trend towards a persistent reduction in the number of WT1+ cells/glomerular cross-
section, suggesting that tight glycaemic and blood pressure control was insufficient to restore 
nephron mass, and that additional therapies may be required to promote regeneration of 
nephrons. Interestingly, more than half of the genes that were specifically down-regulated 
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during reversal are found relatively selectively on endothelial cells. The significance of this is 
uncertain and will be the focus of further investigation. 
We acknowledge that our study has several limitations. As we reversed both hyperglycaemia 
and hypertension simultaneously, we cannot determine which of these factors was primarily 
responsible for the findings observed during reversal. Furthermore, our ability to rapidly 
switch off the mRen2 transgene, enabled blood pressure to be almost normalised, which is 
not always achieved in patients with DN. However, we considered that with suboptimal 
blood pressure control or removal of single injurious stimulus, the presence of on-going 
injury would preclude identification of pathways that promoted repair. Similarly, the study 
was not designed to differentiate between the effects of a reduction in blood pressure versus 
de-activation of the renin-angiotensin system per se. While the period of blood glucose and 
blood pressure control was of similar duration to that employed in other rodent studies
7-10
, in 
this more advanced model of DN it may be that a longer period is required for regression to 
occur, as in human disease
2
. Finally, an additional cohort of animals that were maintained 
diabetic and hypertensive throughout the 36 week period would have been helpful in 
determining whether the reduction in expression of pro-fibrotic genes observed during the 
reversal phase was sufficient to prevent further progression of DN, however this was not the 
primary focus of the current study. Furthermore, the reversal cohort at 36wks was compared 
with the control and injury groups at 28wks, therefore it is possible that the reversal group 
sustained further renal injury during the additional 8 weeks despite reversal of diabetes and 
hypertension due to other factors such as aging, brief hyperglycaemic excursions or the 
effects of anaesthesia during insertion of insulin pellets. This may have biased against 
observing a reduction in renal fibrosis  
In summary, tight control of blood glucose and blood pressure in a novel model of DN is 
sufficient to ameliorate albuminuria and switch off excess ECM production but does not lead 
to regression of scarring or restoration of nephron mass. Transcriptomic profiling has 
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identified genes associated with the fibrotic response, some of which have previously been 
implicated in fibrosis in the kidney and other organs, while others represent novel anti-
fibrotic targets. The data suggest that reparative pathways are initiated, but may be thwarted 
by the continued presence of TIMPs. Further research is warranted to determine whether 
strategies that counteract the inhibitory properties of TIMPs may accelerate resolution of 
fibrosis in the diabetic kidney. 
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Table 1. Pathological parameters in each cohort. Data are means (±SD) *p<0.05, ***p<0.001 
v Controls; 
#
p<0.05 v Injury cohort 
 
 Control  
(n=6) 
Injury  
(n=10) 
Reversal  
(n=9) 
Kidney weight (g) 1.38±0.10 1.64±0.21* 1.53±0.19 
Body weight (g) 460±25.5 350±39.5*** 424±33.2
##
 
Kidney/body weight (%) 0.30±0.01 0.47±0.06*** 0.36±0.03*
#
 
Mean number of glomeruli per tissue 
section 
181±36.0 169±20.5 171±18.7 
Mean hilar glomerular cross-sectional area 
(%age control) 
100 98.0±7.4 100.6±10.0 
Mean number of WT1+ cells/hilar 
glomerular cross-section 
13.6±1.5 11.5±1.8 11.8±1.7 
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Table 2. Metacore process networks and Ingenuity Pathways which are over-represented 
amongst genes that are up-regulated specifically during injury  
 p-value 
Matacore Process Network  
Cell adhesion: cell-matrix interactions 3.22x10
-12
 
Development: cartilage development 1.14x10
-7
 
Cell adhesion: platelet-endothelium-leucocyte interactions 3.94x10
-7
 
Cell adhesion: integrin-mediated cell-matrix interactions 1.99x10
-5
 
Development: regulation of epithelial-to-mesenchymal transition 2.24x10
-4
 
Cell adhesion: glycoconjugates 6.94x10
-4
 
Ingenuity Pathway Analysis  
Hepatic fibrosis/Hepatic stellate cell activation 9.55x10
-7
 
Complement system 2.19x10
-6
 
Acute phase response signalling 1.74x10
-5
 
Intrinsic prothrombin activation pathway 5.62x10
-5
 
Agranulocyte adhesion and diapedesis 5.50x10
-4
 
Role of pattern recognition receptors in recognition of bacteria 
and viruses 
8.51x10
-4
 
Coagulation system 1.66x10
-3
 
Glioma invasiveness signalling 5.50x10
-3
 
Cell cycle: G2/M DNA damage checkpoint regulation 5.50x10
-3
 
Role of Osteoblasts, osteoclasts and chondrocytes in rheumatoid 
arthritis 
8.13x10
-3
 
14-3-3-mediated signalling 1.17x10
-2
 
Fc epsilon RI signalling 2.00x10
-2
 
PDGF signalling 2.40x10
-2
 
Sertoli cell-Sertoli cell junction signalling 3.24x10
-2
 
3-phosphoinositide degradation 3.63x10
-2
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Table 3. Metacore process networks and Ingenuity Pathways which are over-represented 
amongst genes that remain persistently up-regulated during the reversal phase 
 p-value 
Metacore Process Network  
Immune response: T-cell receptor signalling 1.96x10
-5
 
Signal transduction: Wnt signalling 3.58x10
-4
 
Development: blood vessel morphogenesis 4.18x10
-4
 
Cell adhesion: cell-matrix interactions 6.58x10
-4
 
Apoptosis: apoptosis stimulation by external signals 7.78x10
-4
 
Immune response: antigen presentation 9.88x10
-4
 
Immune response: phagocytosis 1.03x10
-3
 
Cytoskeleton: regulation of cytoskeletal rearrangement 1.63x10
-3
 
  
Ingenuity Pathway  
LPS/IL-1 mediated inhibition of RXR function 8.32x10
-3
 
Ceramide signalling 1.62x10
-2
 
ERK/MAPK signalling 1.86x10
-2
 
Apoptosis signalling 2.00x10
-2
 
Cardiac β-adrenergic signalling 2.29x10-2 
Wnt/β-catenin signalling 2.45x10-2 
RhoA signalling 2.69x10
-2
 
Ephrin receptor signalling 2.95x10
-2
 
Protein Kinase A signalling 3.09x10
-2
 
Nrf2-mediated oxidative stress response 3.16x10
-2
 
P70S6K signalling 3.39x10
-2
 
Telomerase signalling 3.55x10
-2
 
Colorectal cancer metastasis signalling 3.80x10
-2
 
Tec kinase signalling 3.98x10
-2
 
Rac signalling 4.57x10
-2
 
3-phosphoinositol biosynthesis 4.79x10
-2
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Figure legends 
 
Figure 1. Albuminuria progressively increases during 28 weeks of hypertension and 
hyperglycaemia, but diminishes rapidly following relative normalisation of blood glucose and 
blood pressure. A. Schemata of the study design. B. Blood glucose concentration C. Blood 
pressure and D. Albumin:Creatinine ratio (ACR) in the injury and reversal cohorts and in 
controls. Data given are means (±SEM). *p<0.05, **p<0.01 v at peak injury  
 
Figure 2. 28 weeks of hyperglycaemia and hypertension resulted in a significant increase in 
glomerulosclerosis and tubulointerstitial fibrosis, which was not reversed following eight 
weeks of relative normalisation of blood sugar and blood pressure. A.  Representative 
periodic-acid schiff staining in the glomeruli with quantification of the glomerulosclerosis 
index. B. Representative Picosirius Red staining in the tubulointerstitium with quantification 
of the tubulointerstitial fibrosis index. Scale bars represent 20M and 100M in the 
glomerular and tubulointerstitial images, respectively. Data given are means (±SEM) 
**p<0.01 and ***p<0.001 v controls 
 
Figure 3. Patterns of differential gene expression in the injury and reversal cohorts. By 
comparing the relative gene expression in the renal cortex of the injury and reversal cohort 
with control rats we identified that: 85 genes were up-regulated specifically during injury and 
reverted towards control levels in the reversal cohort; 314 genes remained persistently up-
regulated despite relative normalisation of blood glucose and blood pressure; 80 genes were 
persistently repressed during both injury and repair; four genes were down-regulated during 
injury, but returned towards normal levels following normalisation of blood glucose and 
blood pressure; 19 and five genes were not differentially expressed during injury, but were 
down- or up-regulated, respectively, during reversal. 
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Figure 4A. Relative expression of myofibroblast markers (transgelin, -smooth muscle 
actin) and prototypic ECM genes (fibronectin and the -1 chain of type I collagen). B. 
Number of i. total (ED-1
+
) ii. classically activated (inducible nitric oxide (NOS
+
)) and iii. 
mannose receptor+ macrophages in the injury and reversal cohorts and in control animals. Ci. 
Number of CD3
+
 T-cells per x400-power tubulointerstitial field and ii. relative expression of 
the Foxp3 gene in the injury and reversal cohorts and in controls *p<0.05, **p<0.01 and 
***p<0.001 v controls; 
#
p<0.05, 
##
p<0.01, 
###
p<0.001 v injury cohort 
 
Figure 5. Despite increased MMP gene expression, MMP activity was reduced during injury 
and reversal compared with controls, but this could be restored by physical separation of the 
MMP:TIMP complexes during zymography. A. Relative expression of the Mmp-2, -7, -12 
and -14 genes; B. Mean gelatinase and collagenase activity and C. Relative expression of i. 
TIMP genes and ii. TIMP-1 protein by Western blotting with quantification by densitometry 
in the renal cortex of controls and in the injury and reversal cohorts. D. Representative 
images and quantification of i. gelatinase and ii. collagenase zymography, demonstrating 
activity of MMP-2 (72kD band) and MMP-1 (52kD band) respectively. Data given are means 
(±SEM). *p<0.05, *p<0.01 and ***p<0.001 v controls; 
##
p<0.01 and 
###
p<0.001 v injury 
cohort 
 
Supplementary Figure. There was a non-significant trend (p=0.07) towards a reduction in 
the number of WT1+ podocytes in animals from both the injury and reversal cohorts 
compared to controls. Figure shows representative images of WT1 staining in the glomeruli 
from animals in each group. Scale bars represent 20M 
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